AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29177979 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser and topical treatment
Number of subjects: 15
Study 29177979 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment only
Number of subjects: 15
Study 28146007 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training 3 days a week for 12 weeks
Number of subjects: 31
Study 28146007 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 31
Study 26682606 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled feedback
Number of subjects: 36
Study 26682606 — intervention group
Group type: COMPARATOR
Intervention: Yoked with self-controlled feedback
Number of subjects: 36
Study 26682606 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited self-controlled feedback
Number of subjects: 36
Study 23193209 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2605541
Number of subjects: 137
Study 23193209 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 137
Study 21512887 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 93
Study 21512887 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 93
Study 18291017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoechoic lesion-directed biopsy
Number of subjects: 1840
Study 18291017 — intervention group
Group type: COMPARATOR
Intervention: Systematic sextant biopsy
Number of subjects: 1840
Study 18291017 — intervention group
Group type: COMPARATOR
Intervention: Repeat and third screening
Number of subjects: 1840
Study 16188911 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1) with a dairy breakfast
Number of subjects: 15
Study 16188911 — intervention group
Group type: COMPARATOR
Intervention: 3-h intravenous infusion of saline with a dairy breakfast
Number of subjects: 15
Study 16188911 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1)
Number of subjects: 15
Study 16188911 — intervention group
Group type: COMPARATOR
Intervention: 3-h intravenous infusion of saline
Number of subjects: 15
Study 12657991 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of tropisetron
Number of subjects: 65
Study 12657991 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 65
Study 10747265 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral piroxicam 1 mg/kg/day
Number of subjects: 58
Study 10747265 — intervention group
Group type: COMPARATOR
Intervention: Soluble aspirin 100 mg/kg/day taken four-hourly
Number of subjects: 58
Study 8936562 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered immediately after fluoxetine
Number of subjects: 32
Study 8936562 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered 2 hours after fluoxetine
Number of subjects: 32
Study 8936562 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered 4 hours after fluoxetine
Number of subjects: 32
Study 8936562 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine on an empty stomach with water only
Number of subjects: 32
Study 1539484 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol 0.5 mg.kg‐1 i.v. in addition to isoflurane
Number of subjects: 24
Study 1539484 — intervention group
Group type: COMPARATOR
Intervention: isoflurane 3.0 vol% in inspiratory gas
Number of subjects: 24
Study 31876772 — intervention group
Group type: EXPERIMENTAL
Intervention: SPC placement by vascular access team (VAT) nurses
Number of subjects: 201
Study 31876772 — intervention group
Group type: COMPARATOR
Intervention: SPC placement by bedside nurses
Number of subjects: 201
Study 28800204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 45
Study 28800204 — intervention group
Group type: COMPARATOR
Intervention: Endoscope-guided coblation tongue base resection
Number of subjects: 45
Study 27875489 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding Hip Screw (SHS)
Number of subjects: 844
Study 27875489 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary Nail
Number of subjects: 844
Study 23647355 — intervention group
Group type: EXPERIMENTAL
Intervention: REDI intervention
Number of subjects: 356
Study 23647355 — intervention group
Group type: COMPARATOR
Intervention: Usual practice Head Start
Number of subjects: 356
Study 23635049 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin (250 mg twice a day for 12 months)
Number of subjects: 274
Study 23635049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 23635049 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 274
Study 19268929 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice a day (group A, 15 subjects)
Number of subjects: 28
Study 19268929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B, 13 subjects)
Number of subjects: 28
Study 18360062 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional coronary artery bypass grafting (group A)
Number of subjects: 65
Study 18360062 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery (group B)
Number of subjects: 65
Study 18360062 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting with modified, rheoparin coated cardiopulmonary bypass (group C)
Number of subjects: 65
Study 16789979 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment for 1 year
Number of subjects: 5143
Study 16789979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5143
Study 16789979 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 5143
Study 16789979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5143
Study 14510745 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric-retentive floating tablet administered with three different solid meals
Number of subjects: 0
Study 10868321 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with varying electrode placement and stimulus intensity
Number of subjects: 59
Study 10868321 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with right unilateral (RUL) electrode placement
Number of subjects: 59
Study 10868321 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 59
Study 9124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (2,000 mg as an intravenous bolus; n = 6)
Number of subjects: 25
Study 9124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (2,000 mg as an intravenous bolus; n = 6)
Number of subjects: 25
Study 9124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg orally; n = 6)
Number of subjects: 25
Study 9124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (250 mg orally; n = 4)
Number of subjects: 25
Study 9124826 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (4.5 x 10(6) U orally; n = 3)
Number of subjects: 25
Study 1389343 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐META adhesive
Number of subjects: 4
Study 1389343 — intervention group
Group type: EXPERIMENTAL
Intervention: copal varnish
Number of subjects: 4
Study 1389343 — intervention group
Group type: EXPERIMENTAL
Intervention: dentin bonding agent
Number of subjects: 4
Study 1389343 — intervention group
Group type: COMPARATOR
Intervention: control, no liner used
Number of subjects: 4
Study 3926504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of insulin (0.67 nmol kg‐1 body weight)
Number of subjects: 6
Study 3926504 — intervention group
Group type: COMPARATOR
Intervention: Control (blood taken before insulin administration)
Number of subjects: 6
Study 31424389 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 309
Study 31424389 — intervention group
Group type: COMPARATOR
Intervention: No psychotropic drugs (NO)
Number of subjects: 309
Study 31424389 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 309
Study 31424389 — intervention group
Group type: EXPERIMENTAL
Intervention: ANL/BZD
Number of subjects: 309
Study 29275871 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban with aspirin
Number of subjects: 0
Study 29275871 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban without aspirin
Number of subjects: 0
Study 29275871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27766505 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement of properly balanced omega-3 and omega-6 fatty acids
Number of subjects: 360
Study 27766505 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine treatment
Number of subjects: 360
Study 27766505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of omega-3 and omega-6 fatty acids with topical cyclosporine
Number of subjects: 360
Study 23959782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea with milk (250 ml black tea plus 50 ml of full fat milk)
Number of subjects: 10
Study 23959782 — intervention group
Group type: COMPARATOR
Intervention: Black tea (300 ml)
Number of subjects: 10
Study 22294639 — intervention group
Group type: EXPERIMENTAL
Intervention: GO‐ON (MW 800‐1500 kD, 25 mg/2.5 ml)
Number of subjects: 217
Study 22294639 — intervention group
Group type: COMPARATOR
Intervention: Hyalgan (MW 500‐730 kD, 20 mg/2 ml)
Number of subjects: 217
Study 22294639 — intervention group
Group type: EXPERIMENTAL
Intervention: GO‐ON
Number of subjects: 217
Study 20165941 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid fluid loading (gelatin 4%, hydroxyethyl starch 6%, albumin 5%)
Number of subjects: 48
Study 20165941 — intervention group
Group type: COMPARATOR
Intervention: Saline fluid loading (normal saline)
Number of subjects: 48
Study 18636279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine and clonidine
Number of subjects: 86
Study 18636279 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine/morphine/clonidine
Number of subjects: 86
Study 15958361 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective ET‐A blockade (BQ‐123 alone)
Number of subjects: 9
Study 15958361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual ET‐A/B blockade (BQ‐123 and BQ‐788)
Number of subjects: 9
Study 12610037 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 452
Study 12610037 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 452
Study 12610037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study 12610037 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (both doses)
Number of subjects: 452
Study 10625126 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house referral
Number of subjects: 177
Study 10625126 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house referral (judged to need hospital referral)
Number of subjects: 177
Study 10625126 — intervention group
Group type: COMPARATOR
Intervention: Usual referral (control)
Number of subjects: 177
Study 7795742 — intervention group
Group type: EXPERIMENTAL
Intervention: High Resolution Computed Tomography (HRCT)
Number of subjects: 27
Study 7795742 — intervention group
Group type: COMPARATOR
Intervention: Chest Radiography (CR)
Number of subjects: 27
Study 7795742 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT (for subjects with simple silicosis)
Number of subjects: 27
Study 7795742 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT (for subjects with conglomerated silicosis)
Number of subjects: 27
Study 7795742 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT (different grades of emphysema)
Number of subjects: 27
Study 7795742 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT (lowest and highest categories of profusion of parenchymal opacities)
Number of subjects: 27
Study 1780819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica 10(‐30) five pills twice daily for five days, starting the day before the event.
Number of subjects: 36
Study 1780819 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 36
Study 7036147 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200mg every 3rd day
Number of subjects: 15
Study 7036147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30957675 — intervention group
Group type: EXPERIMENTAL
Intervention: DV ‐ CTA
Number of subjects: 24
Study 30957675 — intervention group
Group type: COMPARATOR
Intervention: Conventional CTA
Number of subjects: 24
Study 26480029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chairside silica coating with 30 μm SiO2 particles and silanization (Clearfil Porcelain Bond Activator)
Number of subjects: 192
Study 26480029 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hydrofluoric acid etching and silanization
Number of subjects: 192
Study 26480029 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 192
Study 26480029 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-sandblasting with 50 μm Al2 O3 particles
Number of subjects: 192
Study 26480029 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-etching with an Er:YAG laser (10 W)
Number of subjects: 192
Study 26480029 — intervention group
Group type: EXPERIMENTAL
Intervention: ND-Nd:YAG laser etching (0.8 W)
Number of subjects: 192
Study 26480029 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-etching with a femtosecond laser (860 mW)
Number of subjects: 192
Study 25331367 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized preoperative and postoperative strength and endurance exercises and progressive postoperative mobilization, initiated 2 weeks before surgery.
Number of subjects: 107
Study 25331367 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen comprising regular fast-track principles (Control group).
Number of subjects: 107
Study 25331367 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized preoperative and postoperative strength and endurance exercises and progressive postoperative mobilization.
Number of subjects: 107
Study 25166445 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐LANSS score
Number of subjects: 148
Study 25166445 — intervention group
Group type: COMPARATOR
Intervention: LANSS and NPQ scores
Number of subjects: 148
Study 23017815 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial measurement of the cardiovascular biomarker midregion proadrenomedullin (MR‐proADM)
Number of subjects: 0
Study 23017815 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk scores
Number of subjects: 0
Study 19237811 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for contrast induced nephropathy (CIN) after PCI
Number of subjects: 247
Study 17519400 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine qd for 7 days
Number of subjects: 19
Study 17519400 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate qd for 7 days
Number of subjects: 19
Study 17519400 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine plus 300 mg tenofovir disoproxil fumarate qd for 7 days
Number of subjects: 19
Study 16236942 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg before anesthesia induction and 0.5 mg/kg after 8 h; n = 10)
Number of subjects: 20
Study 16236942 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (n = 10)
Number of subjects: 20
Study 16236942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study 12154258 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopic (NIRS) topography
Number of subjects: 6
Study 12154258 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI)
Number of subjects: 6
Study 12154258 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 6
Study 12154258 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 6
Study 10202874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally twice daily from the first day of COH until the day of hCG injection)
Number of subjects: 70
Study 10202874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 70
Study 10202874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7750319 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss combined with sleeping on side and nasal spray
Number of subjects: 19
Study 2316014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for three months)
Number of subjects: 21
Study 2316014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g corn oil for three months)
Number of subjects: 21
Study 6270966 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant local radiation therapy
Number of subjects: 37
Study 6270966 — intervention group
Group type: COMPARATOR
Intervention: Cyclic treatment with 5‐Fluorouracil, Methotrexate and Chlorambucil
Number of subjects: 37
Study 30743194 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-nicotine-content cigarettes (VLNCCs)
Number of subjects: 238
Study 30743194 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content cigarettes
Number of subjects: 238
Study 28257941 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude at 4300 m
Number of subjects: 12
Study 28257941 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude at 2150 m
Number of subjects: 12
Study 28257941 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude at sea-level
Number of subjects: 12
Study 25791613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h on days 1 to 3, followed by 4 mg/24 h on days 4 to 6)
Number of subjects: 48
Study 25791613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h and 4 mg/24 h)
Number of subjects: 48
Study 25791613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 48
Study 25791613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23713936 — intervention group
Group type: EXPERIMENTAL
Intervention: Bagolini striated glasses (BSG)
Number of subjects: 52
Study 23713936 — intervention group
Group type: COMPARATOR
Intervention: No Bagolini striated glasses (BSG)
Number of subjects: 52
Study 21233603 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 81
Study 21233603 — intervention group
Group type: COMPARATOR
Intervention: Definitive Chemoradiation (CRT)
Number of subjects: 81
Study 21233603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Surgery and CRT)
Number of subjects: 81
Study 21233603 — intervention group
Group type: COMPARATOR
Intervention: Surgery and CRT
Number of subjects: 81
Study 19325138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 0
Study 19325138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17251316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy Asthma Care Program (PACP)
Number of subjects: 396
Study 17251316 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 396
Study 15523984 — intervention group
Group type: EXPERIMENTAL
Intervention: CustomCornea
Number of subjects: 93
Study 15523984 — intervention group
Group type: COMPARATOR
Intervention: CustomVue
Number of subjects: 93
Study 11116451 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic prednisolone mixture 2 mg/kg daily for 5 days
Number of subjects: 147
Study 11116451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 9378829 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser with air/water surface cooling
Number of subjects: 42
Study 9378829 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser without air/water surface cooling
Number of subjects: 42
Study 9378829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with air/water surface cooling
Number of subjects: 42
Study 9378829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser without air/water surface cooling
Number of subjects: 42
Study 9378829 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with air/water surface coolant
Number of subjects: 42
Study 9378829 — intervention group
Group type: EXPERIMENTAL
Intervention: S/RP only
Number of subjects: 42
Study 9378829 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 42
Study 1536632 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 59
Study 1536632 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 59
Study 1536632 — intervention group
Group type: COMPARATOR
Intervention: Control (symptomatic drugs only)
Number of subjects: 59
Study 6388521 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 10
Study 6388521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31689674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 1324
Study 31689674 — intervention group
Group type: COMPARATOR
Intervention: Non-hysteroscopy
Number of subjects: 1324
Study 29405867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating abuse prevention workshop
Number of subjects: 85
Study 29405867 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 85
Study 27038012 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensory storytelling (MSST)
Number of subjects: 76
Study 27038012 — intervention group
Group type: COMPARATOR
Intervention: Regular storytelling
Number of subjects: 76
Study 25818931 — intervention group
Group type: EXPERIMENTAL
Intervention: PostCon (ischemic postconditioning)
Number of subjects: 87
Study 25818931 — intervention group
Group type: COMPARATOR
Intervention: Control (no ischemic postconditioning)
Number of subjects: 87
Study 22505744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 12
Study 22505744 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosols
Number of subjects: 12
Study 22505744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot humid air (HA)
Number of subjects: 12